These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2653714)

  • 1. A review of cephalosporin metabolism: a lesson to be learned for future chemotherapy.
    Jones RN
    Diagn Microbiol Infect Dis; 1989; 12(1):25-31. PubMed ID: 2653714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefotaxime, cephalothin, and cephapirin: antimicrobial activity and synergy studies of cephalosporins with significant in vivo desacetyl metabolite concentrations.
    Jones RN; Packer RR
    Diagn Microbiol Infect Dis; 1984 Jan; 2(1):65-8. PubMed ID: 6100364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population analysis of susceptibility to cefotaxime and desacetyl-cefotaxime in Staphylococcus and Enterobacteriaceae.
    Hansen BG; Søgaard P
    Acta Pathol Microbiol Immunol Scand B; 1985 Jun; 93(3):243-7. PubMed ID: 3875967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro synergy between cefotaxime and its main metabolite, desacetylcefotaxime].
    Kobayashi S; Arai S; Hayashi S; Sakaguchi T; Kawana R
    Jpn J Antibiot; 1988 May; 41(5):594-601. PubMed ID: 3216482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of cefotaxime alone and in combination with desacetylcefotaxime against strains of Staphylococcus aureus that produce variants of staphylococcal beta-lactamase.
    Stratton CW; Kernodle DS; Eades SC; Weeks LS
    Diagn Microbiol Infect Dis; 1989; 12(1):57-65. PubMed ID: 2785444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antibacterial interaction of cefotaxime and desacetylcefotaxime.
    Molinari G; Saverino D; Paglia P; Debbia EA; Schito GC
    J Chemother; 1991 Feb; 3(1):6-12. PubMed ID: 2019866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review.
    Jones RN
    Diagn Microbiol Infect Dis; 1995; 22(1-2):19-33. PubMed ID: 7587039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the in vitro action and interaction of cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides spp.
    Aldridge KE
    Diagn Microbiol Infect Dis; 1989; 12(1):45-50. PubMed ID: 2714072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A reassessment of the activity of the third-generation cephalosporins against anaerobes and Staphylococcus aureus.
    Canawati HN
    Am J Surg; 1992 Oct; 164(4A Suppl):24S-27S. PubMed ID: 1443357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interaction of cefotaxime and its metabolite desacetylcefotaxime demonstrated by drug-impregnated disks.
    Stevens DL; Bergstrom R; Gibbons A
    Diagn Microbiol Infect Dis; 1989; 12(1):73-80. PubMed ID: 2653715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro comparison of the activity of cefotaxime and desacetylated cefotaxime and of their combination.
    Nanetti A; La Placa M
    J Chemother; 1990 Jun; 2(3):159-63. PubMed ID: 2380765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of cefotaxime/desacetylcefotaxime with two aminoglycosides against gram-negative pathogens: an example of interactive synergy.
    Jenkins SG
    Diagn Microbiol Infect Dis; 1989; 12(1):51-5. PubMed ID: 2714073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial activity of cefotaxime, desacetylcefotaxime, and the combination of the two.
    Friis H
    Diagn Microbiol Infect Dis; 1989; 12(1):67-72. PubMed ID: 2714074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of ceftazidime and ceftriaxone.
    Keenholtz SL; Jacobus NV; Tally FP; Gorbach SL
    Clin Ther; 1983; 5(6):603-16. PubMed ID: 6313195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The activity of cefotaxime and desacetylcefotaxime alone and in combination against anaerobes and staphylococci.
    Jones RN; Barry AL; Packer RR
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):37S-46S. PubMed ID: 6086217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefotaxime: microbiology, pharmacology, and clinical use.
    Dudley MN; Barriere SL
    Clin Pharm; 1982; 1(2):114-24. PubMed ID: 6309465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative antimicrobial activity of aminothiazolyl methoxyimino cephalosporins against anaerobic bacteria, including 100 cefoxitin-resistant isolates.
    Jones RN; Barry AL; Aldridge KE; Gerlach EH
    Diagn Microbiol Infect Dis; 1987 Nov; 8(3):157-63. PubMed ID: 3501976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels and urinary excretion of parent antibiotics and desacetyl forms after parenteral administration of cephalothin and cephapirin.
    Shimizu T
    Jpn J Antibiot; 1975 Aug; 28(4):628-33. PubMed ID: 1160152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cooperation of cefotaxime and desacetyl-cefotaxime with respect to antibacterial activity and beta-lactamase stability.
    Limbert M; Seibert G; Schrinner E
    Infection; 1982; 10(2):97-100. PubMed ID: 6284653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of cefotaxime and desacetylcefotaxime against pathogenic bacteria. Assessment with the serum bactericidal test.
    Reller LB
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):55S-61S. PubMed ID: 6086219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.